Related references
Note: Only part of the references are listed.Public biotech 2013-the numbers
Stacy Lawrence et al.
NATURE BIOTECHNOLOGY (2014)
Biopharmaceutical benchmarks 2014
Gary Walsh
NATURE BIOTECHNOLOGY (2014)
Interchangeability, immunogenicity and biosimilars
Hans C. Ebbers et al.
NATURE BIOTECHNOLOGY (2012)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years
M. Miles Braun et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Biosimilars: A regulatory review
Pia Furlani
DRUG INFORMATION JOURNAL (2008)
Trends in the globalization of clinical trials
Fabio A. Thiers et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The Cost of Biopharmaceutical R&D: Is Biotech Different?
Joseph A. DiMasi et al.
MANAGERIAL AND DECISION ECONOMICS (2007)
The rise of venture capital and biotechnology in the US and Europe
DP Lee et al.
NATURE BIOTECHNOLOGY (2005)
Pegylation - A novel process for modifying pharmacokinetics
JM Harris et al.
CLINICAL PHARMACOKINETICS (2001)
Share Paper
